Olaparib for Metastatic Castration-resistant Prostate Cancer
PRostate Olaparib Real World Evidence Study
- Age
- 18 and older
- Sex
- Male
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- AstraZeneca · Industry
This trial is looking for adult men with metastatic castration-resistant prostate cancer who have started treatment with olaparib. Participants will have their data collected to help understand the real-world impact of this treatment.
You may be able to join if
- I am a man aged 18 or older.
- I have metastatic castration-resistant prostate cancer.
- I have started olaparib treatment within the last two months.
- I have agreed to have my data collected for this study.
You may not be able to join if
- I do not agree to let my data be collected.
- I participated in another clinical trial with a new prostate cancer drug in the last 30 days.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
Loading trial locations…
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
CONTACT